Download PDF
Thromb Haemost 1983; 49(02): 138-141
DOI: 10.1055/s-0038-1657339
Original Article
Schattauer GmbH Stuttgart

Interaction of Heparin with Lipoproteins – Role of the Complex in the Inactivation of Thrombin and Plasmin

E Kecskés
The Second Institute of Biochemistry, Semmelweis University Medical School, Budapest, Hungary
,
K G Büki
The Second Institute of Biochemistry, Semmelweis University Medical School, Budapest, Hungary
,
P I Bauer
The Second Institute of Biochemistry, Semmelweis University Medical School, Budapest, Hungary
,
R Machovich
The Second Institute of Biochemistry, Semmelweis University Medical School, Budapest, Hungary
,
I Horváth
The Second Institute of Biochemistry, Semmelweis University Medical School, Budapest, Hungary
› Author Affiliations
Further Information

Publication History

Received 16 September 1982

Accepted 18 February 1983

Publication Date:
18 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

Heparin forms a complex with human low density lipoprotein (LDL) in the presence of Ca2+. The complex is dissociable by 0.5 M NaCI. Thrombin and plasmin causes the dissociation of the LDL-heparin complex, whereas factor Xa does not. Heparin, complexed with LDL, retains its enhancing effect on the rate of thrombin and plasmin inactivation by antithrombin III. LDL isolated from the plasma of persons with different pathological conditions did not alter the rate of thrombin inactivation by antithrombin III either in the absence or in the presence of heparin. Heparin seems to maintain its biological functions when it is in a complex with LDL.

Keywords

Heparin - High density lipoproteins - Low density lipoproteins - Thrombin - Plasmin - Factor Xa - Antithrombin III
 

  • References

  • 1 Estes JW. Clinical pharmacokinetics of heparin. Clin Pharmacokinet 1980; 5: 204-220
    CrossrefPubMedGoogle Scholar
  • 2 Marciniak E. Binding of heparin in vitro and in vivo to plasma proteins. J Lab Clin Med 1974; 84: 344-356
    PubMedGoogle Scholar
  • 3 Srinivasan SR, Randhnakrishnamurity B, Berenson G. Studies on the interaction of heparin with serum lipoproteins in the presence of Ca2+, Mg2+ and Mn2+ . Arch Biochem Biophys 1975; 170: 334-340
    CrossrefPubMedGoogle Scholar
  • 4 Shelburne FA, Quartfordt SH. The interaction of heparin with an apoprotein of human very low density lipoprotein. J Clin Invest 1977; 60: 944-950
    CrossrefPubMedGoogle Scholar
  • 5 Mookerjea S. Mechanism of heparin and serum lipoprotein interaction: Effect of calcium, phosphorylcholine and a serum fraction. Can J Biochem 1978; 56: 746-752
    CrossrefPubMedGoogle Scholar
  • 6 Skinner ER, Rooke JA. Fractionation of rat plasma lipoproteins by affinity chromatography on heparin-Sepharose. Comp Biochem Physiol 1980; 65 B: 645-650
    PubMedGoogle Scholar
  • 7 MacGregor JR, Lane DA, Kakkar VV. The anti-heparin properties of human low-density lipoprotein. Biochim Biophys Acta 1980; 617: 472-479
    CrossrefPubMedGoogle Scholar
  • 8 Lane DA, MacGregor JR. Low-density lipoprotein: a selective inhibitor of the heparin-accelerated neutralisation of factor Xa by antithrombin III. In: Chemistry and Biology of Heparin. Lundblad RL, Brown WV, Mann KG, Roberts HR. (Eds), pp. 301-307 Elsevier – North Holland: 1981
    Google Scholar
  • 9 Rosenberg R, Oosta GM, Jordan RE, Gardner WT. Mechanism of antithrombin action and the structural basis of heparin's anticoagulant function. In: Chemistry and Biology of Heparin. Lundblad RL, Brown WV, Mann KG, Roberts HR. (Eds), pp. 249-269 Elsevier – North Holland:
    Google Scholar
  • 10 Machovich R, ArSnyi P. Effect of heparin on thrombin inactivation by antithrombin HI. Biochem J 1978; 173: 869-875
    CrossrefPubMedGoogle Scholar
  • 11 Jaques LB, Kavanagh LW, Kuo SH. Variations in chemical parameters and anticoagulant potencies of commercial heparin and its relation to the problem of heparin standardized for clinical use. Thromb Res 1973; 3: 295-306
    CrossrefPubMedGoogle Scholar
  • 12 Fenton II JW, Fasco MJ, Stackrow AB. Human thrombins. J Biol Chem 1977; 252: 3587-3598
    PubMedGoogle Scholar
  • 13 Lundblad RL, Uhteg LC, Vogel NC, Kingdon HS, Mann KG. Preparation and partial characterization of two forms of bovine thrombin. Biochem Biophys Res Commun 1975; 66: 428-489
    PubMedGoogle Scholar
  • 14 Deutsch DG, Mertz ET. Plasminogen: purification from human plasma by affinity chromatography. Science 1970; 170: 1095-1096
    CrossrefPubMedGoogle Scholar
  • 15 Machovich R, Bauer PI, Arányi P, Kecskés É, Büki KG, Horváth I. Kinetic analysis of the heparin enhanced plasmin-antithrombin III reaction. Apparent catalytic role of heparin. Biochem J 1981; 199: 521-526
    CrossrefPubMedGoogle Scholar
  • 16 Blaskd G, Machovich R. Decreased heparin sensitivity of cyclo-hexanedione-modified factor Xa. Thromb Haemostas 1979; 42: 556-563
    PubMedGoogle Scholar
  • 17 Wickerhauser M, Williams C, Mercier J. Development of large scale fractionation methods. VII. Preparation of anti thrombin III concentrate. Vox Sang 1979; 36: 281-293
    CrossrefPubMedGoogle Scholar
  • 18 Orakzai AS, Machovich R. Inactivation of α- and β-thrombin by heat-defibrinated human plasma. Effect of heparin. Thromb Res 1977; 10: 813-822
    CrossrefPubMedGoogle Scholar
  • 19 Havel RJ, Eder HA, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 1955; 34: 1345-1353
    CrossrefPubMedGoogle Scholar
  • 20 Hatton MWC, Berryl RL, Machovich R, Regoeczi E. Tritiation of commercial heparin by reaction with NaB3H4: Chemical analysis and biological properties of the product. Anal Biochem 1980; 106: 417-427
    CrossrefPubMedGoogle Scholar
  • 21 Jaques LB, Bell HS. The determination of heparin. Methods Biochem Anal 1959; 7: 253-309
    PubMedGoogle Scholar
  • 22 Lowry OH, Rosebrough HJ, Farr AL, Randall RJ. Protein measurement with folin phenol reagent. J Biol Chem 1951; 193: 265-275
    PubMedGoogle Scholar
  • 23 Summaria L, Hsieh B, Grosskopf NR, Robbins KC, Barlow GH. The isolation and characterization of the S-carboxymethyl (light) chain derivative of human plasmin. J Biol Chem 1967; 242: 5046-5052
    PubMedGoogle Scholar
  • 24 Miller-Andersson M, Borg H, Andersson LO. Purification of antithrombin III by affinity chromatography. Thromb Res 1974; 5: 439-452
    CrossrefPubMedGoogle Scholar
  • 25 Hilbom JC, Anastassiadis PA. Estimation of the molecular weights of acidic mucopolysaccharides by polyacrylamide gel electrophoresis. Anal Biochem 1971; 31: 51-59
    PubMedGoogle Scholar
  • 26 Machovich R, Regoeczi E, Hatton C. The influence of heparin, NaCI and CaCl2 on the rate of the thrombin-antithrombin III reaction. Thromb Res 1979; 15: 821-834
    CrossrefPubMedGoogle Scholar
  • 27 Gitel SN. Evidence of catalytic role of heparin in anticoagulation reactions. Adv Exp Med Biol 1975; 52: 243-247
    PubMedGoogle Scholar
  • 28 Stürzebecher J, Markwardt F. Role of heparin in the inhibition of thrombin, Factor Xa and plasmin by antithrombin III. Thromb Res 1977; 11: 835-846
    CrossrefPubMedGoogle Scholar
  • 29 Griffith MJ, Kingdon HS, Lundblad RJ. Inhibition of the heparin- antithrombin III/thrombin reaction by active site blocked-thrombin. Biochem Biophys Res Commun 1979; 87: 686-692
    CrossrefPubMedGoogle Scholar
  • 30 Machovich R. Mechanism of action of heparin through thrombin on blood coagulation. Biochim Biophys Acta 1975; 412: 13-17
    CrossrefPubMedGoogle Scholar
  • 31 Hatton MWC, Regoeczi E. The inactivation of thrombin and plasmin by antithrombin in in the presence of Sepharose-heparin. Thromb Res 1977; 10: 645-660
    CrossrefPubMedGoogle Scholar
  • 32 Machovich R, Staub M, Patthy L. Decreased heparin sensitivity of cyclohexanedione-modified thrombin. Eur J Biochem 1978; 83: 473-477
    PubMedGoogle Scholar
  • 33 Griffith MJ. Kinetic analysis of the heparin enhanced antithrombin III/thrombin reaction. J Biol Chem 1979; 254: 12044-12049
    PubMedGoogle Scholar
  • 34 Smith GF, Sundboom JL. Heparin-plasmin and heparin-trypsin complexes in solution. Relevance to α-antithrombin function and heparin pharmacology. In: Chemistry and Biology of Heparin. Lundblad RL, Brown WV, Mann KG, Roberts HR. (Eds), pp. 317-323 Elsevier – North Holland: 1981
    Google Scholar
  • 35 Pan YT, Kruski AW, Elbein AD. Binding of [3H]-heparin to human plasma low density lipoprotein. Arch Biochem Biophys 1978; 189: 231-240
    CrossrefPubMedGoogle Scholar
  • 36 Smith GF, Sundboom JL. Heparin and protease inhibition. I. Heparin complexes with thrombin, plasmin and trypsin. Thromb Res 1981; 22: 103-114
    CrossrefPubMedGoogle Scholar